A thorough QTC study to assess the effect of Cotadutide on cardiac repolarization in healthy participants

Exclusion Criteria

• • History or presence of any clinically significant disease or disorder.
• • History or presence of gastrointestinal, hepatic or renal disease, or any other condition (including gastrointestinal surgery) known to interfere with absorption, distribution, metabolism, or excretion of drugs.
• • History of acute or chronic pancreatitis.
• • Family history of sudden cardiac death before the age of 50 of a first-degree relative.
• • History of additional risk factors for Torsade de Pointes (eg, heart failure, clinically important bradycardia and electrolyte disturbances eg, hypokalemia, hypocalcemia, hypomagnesemia or family history of long QT syndrome).
• • History of neoplastic disease
• • Any clinically significant abnormalities in clinical chemistry, hematology, urinalysis results or vital signs.
• • Any clinically significant abnormalities in rhythm, conduction, or morphology of the 12-lead resting electrocardiogram (ECG).
• • Any positive result on screening for serum hepatitis B surface antigen OR anti-HBc antibody, indicative of active hepatitis B (ie, participants with positive anti-HBc antibody result are acceptable if anti HBc IgM antibodies are negative), hepatitis C antibody, and Human immunodeficiency virus (HIV) antibody.
• • Current smokers or those who have smoked or used nicotine products (including e-cigarettes).
• • Known or suspected history of alcohol or drug abuse or excessive intake of alcohol.
• • Use of drugs with enzyme-inducing properties such as St John’s Wort.
• • Participant has a positive test result for SARS-CoV-2 RT-PCR during screening period or at baseline.
• • Participant has clinical signs and symptoms consistent with COVID-19 or a history of severe COVID-19 (hospitalization, extracorporeal membrane oxygenation, mechanically ventilated).